Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1
Authors (first, second and last of 9)
Volume 15, issue 1, December 2022
178 articles in this issue
-
-
-
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
Authors (first, second and last of 47)
-
Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients
Authors (first, second and last of 13)
-
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease
Authors (first, second and last of 7)
-
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)
Authors (first, second and last of 9)
-
CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR
Authors (first, second and last of 13)
-
Recent advances in therapeutic strategies for triple-negative breast cancer
Authors (first, second and last of 7)
-
Posttranslational control of lipogenesis in the tumor microenvironment
Authors (first, second and last of 6)
-
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response
Authors (first, second and last of 7)
-
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy
Authors (first, second and last of 4)
-
-
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL
Authors (first, second and last of 101)
-
Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry
Authors (first, second and last of 17)
-
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway
Authors (first, second and last of 15)
-
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
Authors (first, second and last of 23)
-
RETRACTED ARTICLE: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA
Authors (first, second and last of 13)
-
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
Authors (first, second and last of 15)
This is part of 2 collections:
-
Targeting macrophages in hematological malignancies: recent advances and future directions
Authors (first, second and last of 5)
-
Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation
Authors (first, second and last of 14)
-
Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients
Authors (first, second and last of 10)
-
Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry
Authors (first, second and last of 29)
-
Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma
Authors (first, second and last of 12)
-
Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study
Authors (first, second and last of 12)
-
Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity
Authors (first, second and last of 7)
-
Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents
Authors (first, second and last of 11)
-
Correction: hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype
Authors (first, second and last of 12)
-
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis
Authors (first, second and last of 17)
-
Correction: Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer
Authors (first, second and last of 19)
-
hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype
Authors (first, second and last of 12)
-
-
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management
Authors (first, second and last of 7)
-
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
Authors (first, second and last of 45)
-
-
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
Authors (first, second and last of 8)
-
Allosteric activation of the metabolic enzyme GPD1 inhibits bladder cancer growth via the lysoPC-PAFR-TRPV2 axis
Authors (first, second and last of 12)
-
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation
Authors (first, second and last of 18)
-
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
Authors (first, second and last of 9)
-
A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase
Authors (first, second and last of 5)
-
Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy
Authors (first, second and last of 10)
-
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia
Authors (first, second and last of 13)
This is part of 2 collections:
-
Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors
Authors (first, second and last of 15)
-
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)
Authors (first, second and last of 30)
-
Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression
Authors (first, second and last of 16)
-
Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application
Authors (first, second and last of 9)
-
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling
Authors (first, second and last of 19)
-
The regulation of insulin receptor/insulin-like growth factor 1 receptor ratio, an important factor for breast cancer prognosis, by TRIP-Br1
Authors (first, second and last of 11)
-
Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients
Authors (first, second and last of 5)
-
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence
Authors (first, second and last of 6)
-
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
Authors (first, second and last of 10)
